A peer review confirmed that the BioNTech-Pfizer vaccine is effective against two variants of the coronavirus, the companies announced Monday.
The magazine, which was published in the journal Nature medicine, supported the results of a study completed by Pfizer and the University of Texas in late January.
When the study was originally launched, BioNTech and Pfizer said its discovery suggests that no new vaccine will be needed to fight the coronavirus mutations first discovered in the United Kingdom and South Africa.
However, the continuous transformation of the deadly virus makes clinical data and constant observation imperative. Experts say it is not a foregone conclusion that the vaccines currently used will remain effective against possible new variants of the virus in the future.
Spahn expresses confidence in vaccines
On Monday, German Health Minister Jens Spahn expressed confidence in the effectiveness of all three vaccines approved by the European Union. This was followed by the announcement by the South African government that it would suspend the planned launch of the AstraZeneca vaccine.
South Africa justified the decision by indicating the low efficacy of the vaccine against mild to moderate infection from variant B.1351, which is currently dominant in the country. Spahn pointed out that the three EU-approved vaccines were highly effective against serious infections.
Germany is changing policy to avoid waste
Spahn also announced a change in vaccination policy in Germany. People, such as health workers and emergency personnel, would be allowed to jump in and receive shots earlier than expected, to avoid wasting vaccines that have already been opened and need to be used, or thrown at the end of each day.
The minister, however, urged those “who have political responsibility to set a good example”, patiently waiting their turn. The statement came in the light of news that some people used the power of their positions to get vaccinated, despite being in risk-free groups.
Spahn said teachers and students would remain low on the list, despite talks about reopening schools, stressing that those most in need – those over 80, as well as those who work and live in nursing homes – would remain at the forefront. .
js / rt (AFP, Reuters)